MedTrace Logo

Sildenafil in Heart Failure With Reactive Pulmonary Hypertension

NCT02304705 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2019-11-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Sildenafil 20mg taken three times a day is effective in the treatment of Heart Failure with Reactive Pulmonary Hypertension. This is a double-blind, placebo controlled trial.

Conditions

  • Heart Failure With Reactive Pulmonary Hypertension

Interventions

DRUG

Sildenafil

20 mg three times daily by mouth for 90 days

DRUG

Placebo

One capsule three times daily by mouth for 90 days

Sponsors & Collaborators

  • Maya Guglin

    lead OTHER

Principal Investigators

  • Maya E Guglin, MD, PhD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-06-30
Completion
2017-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02304705 on ClinicalTrials.gov